Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Gaucher Disease Type 1
Interventions
DRUG

N-acetylcysteine

1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.

Trial Locations (2)

10016

RECRUITING

New York University, New York

55455

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

Rare Diseases Clinical Research Network

NETWORK

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Lysosomal Disease Network

OTHER

lead

University of Minnesota

OTHER